SAMSUNG PHARM. Co (001360) Fair Value & Analysis
Healthcare · KR · Market cap 130B KRW
Fair value as of: Jun 25, 2026
From 8 valuation models · updated 5 days ago
Share price −21.5% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,308 KRW – 2,274 KRW · fair‑value band 1,136 KRW – 2,022 KRW · the 1,308 KRW price screens above the 1,262 KRW fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SAMSUNG PHARM. Co (001360) currently trades at 1,308 KRW, while our model-based Fair Value estimate is 1,262 KRW — implying the stock looks roughly 3.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, SAMSUNG PHARM. Co generated revenue of 44.3B KRW at a net margin of 28.7%. Revenue grew 122.7% year over year. It earns a return on equity of -4.4%. Net debt stands at 6.1B KRW. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamins, antibiotics, and others. The company also provides medicines for the digestive system, medicines for liver disorders, medicines for the circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, cold medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SAMSUNG PHARM. Co reported revenue of 46.1B KRW in FY2025 versus 54.9B KRW in FY2021, a compound −4.3%/yr. Reported net income was 11.5B KRW in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.60 | HK$15.73 | -47% |
| Divi's Laboratories Limited DIVISLAB | ₹6,747 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SAMSUNG PHARM. Co (001360) undervalued?
What is the fair value of 001360?
What is the quality score of 001360?
What is the revenue of SAMSUNG PHARM. Co (001360)?
What is the net profit margin of 001360?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.